UBS Group
STLN

UBS Group’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

UBS Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.76M Buy
574,652
+286,966
+100% +$880K ﹤0.01% 5089
2025
Q4 		$1.02M Sell
287,686
-768,176
-73% -$2.85M ﹤0.01% 5554
2025
Q3 		$3.68M Buy
1,055,862
+635,489
+151% +$2.18M ﹤0.01% 4352
2025
Q2 		$862K Buy
420,373
+410,296
+4,072% +$1.03M ﹤0.01% 5573
2025
Q1 		$11.5K Sell
10,077
-51,884
-84% -$40.2K ﹤0.01% 8549
2024
Q4 		$19.1K Buy
+61,961
New +$16.1K ﹤0.01% 7902
2024
Q2 		– Sell
-10,326
Closed -$16.3K – 10090
2024
Q1 		$16.3K Buy
+10,326
New +$19.6K ﹤0.01% 7010
2023
Q3 		– Sell
-2,414
Closed -$1.33K – 9967
2023
Q2 		$1.33K Sell
2,414
-9,124
-79% -$4.83K ﹤0.01% 7944
2023
Q1 		$7.82K Buy
11,538
+5,377
+87% +$6.86K ﹤0.01% 7775
2022
Q4 		$10.2K Buy
6,161
+4,577
+289% +$12.8K ﹤0.01% 8563
2022
Q3 		$7K Buy
1,584
+1,071
+209% +$6.3K ﹤0.01% 8906
2022
Q2 		$3K Buy
+513
New +$3.74K ﹤0.01% 9367
2022
Q1 		– Sell
-1,859
Closed -$18K – 10905
2021
Q4 		$18K Sell
1,859
-28,584
-94% -$254K ﹤0.01% 7992
2021
Q3 		$303K Buy
30,443
+29,554
+3,324% +$293K ﹤0.01% 5036
2021
Q2 		$9K Buy
+889
New +$8.95K ﹤0.01% 8160
2021
Q1 		– Sell
-502
Closed -$5K – 9469
2020
Q4 		$5K Sell
502
-1,044
-68% -$10.7K ﹤0.01% 7847
2020
Q3 		$16K Buy
+1,546
New +$16.1K ﹤0.01% 6484

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's STLN Position: Q1 2026 in Review

UBS Group increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 100% in Q1 2026, buying an estimated $880K and bringing the position to 574,652 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #5089.

UBS Group first reported a position in STLN in Q3 2020 and has held it in 17 quarters since. The position peaked at $3.68M in Q3 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • UBS Group held 574,652 shares of Starling Oncology Institute, Inc. Common Stock worth $1.76M as of Q1 2026.
  • UBS Group bought 286,966 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $880K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5089 holding.
  • UBS Group first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2020 and has held it in 17 quarters since.
  • UBS Group's Starling Oncology Institute, Inc. Common Stock position peaked at $3.68M in Q3 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.